Six of Celgene's (CELG) clinical trials were put on hold on Thursday, but the company's growth will remain outstanding for the coming years. The strong growth outlook, a deep pipeline and a valuation that is not very high make Celgene attractive, I believe.
Merck's (MRK) Keytruda has led to problems in a drug trial where the drug was tested for the treatment of multiple myelomas in combination with immunomodulatory agents, which has made the FDA put a partial or full clinical hold on a couple of other clinical trials as well, including six of Celgene's trials under its Fusion program.
